Priorities in Addressing Global Health

Developing and Improving Access to New Products for Diseases with no Treatments

Chugai will create and develop innovative products for unmet medical needs, such as treatments for diseases that currently have no cure, by using its drug discovery technology centered on biotechnologies obtained through its research and development.
These products are only meaningful when they reach the people who need them. We are contributing to improving access to medicines not only in developed countries but also in developing countries by leveraging our strengths in various disease-specialized areas and technologies.

WFH Aid program

Chugai cooperates with the World Federation of Hemophilia (WFH) to provide the medicine we created to hemophilia patients in developing countries where access to treatment is extremely limited. Chugai attempts to improve treatment access including medical equipment and education for healthcare professionals with Roche.

News Release: Together with Roche, Chugai Joins the World Federation of Hemophilia Humanitarian Aid Program (Feb 6, 2019) [PDF 178KB]

Industry-government-academia collaboration for Rheumatoid medicine

Through industry-government-academia collaboration, Chugai contributes to the realization and quality improvement of sustainable rheumatology care in Indonesia.

Activity Reports: Project to Promote International Industry-Government-Academia Collaboration in Medical Care for Rheumatic Disease

Development Project for Anti-Dengue Virus Antibody

Chugai is conducting the research and development of therapeutic agents that utilize antibody technology to treat dengue fever, one of the neglected tropical diseases that prevail in developing countries.

News Release: Chugai - A*STAR Joint Development Project for Anti-Dengue Virus Antibody Selected as Grant Recipient by the GHIT Fund (Mar 30, 2017) [PDF 74KB]

Improving Access to Sustainable Healthcare

Access to healthcare is a complex challenge and there are no one-size-fits-all solutions. As access barriers vary widely depending on the country or region, it is important to identify local needs and region-specific barriers, and then develop and implement appropriate plans. By collaborating and cooperating with various public institutions, NGOs, patient associations, and pharmaceutical companies, we contribute to the improvement of sustainable health care systems, mainly in low- and middle-income countries.

Non-Communicable Diseases (NCDs)

We cooperate with NGOs to carry out support activities that meet local needs. In addition, in order to achieve solutions to issues where individual companies have limitations, we launched the industry partnership called Access Accelerated together with more than 20 global pharmaceutical companies for the prevention, diagnosis, and treatment of non-communicable diseases (NCDs) in low- and middle-income countries. Furthermore, AA has developed a method to measure and evaluate the effects and impact of individual activities in cooperation with a third-party organization. By aggregating and sharing the results of each activity, we aim to establish a mechanism to review and improve its activities.

News Release: Chugai to Join Global Initiative for Addressing Rise of Non-Communicable Diseases in Low and Lower-Middle Income Countries (Jan 18, 2017) [PDF 71KB]

Activity Reports: Health Camp Against NCDs and Helping Safer Childbirth

ACCESS ACCELERATED Logo
AMDA MINDS Logo

Mobile medical clinics in Myanmar

Oncology Area

Healthcare challenges are multifaceted, and improving one aspect of healthcare is often not enough. In particular, for complex treatments such as cancer, improvements in various fields are required for successful treatment, such as diagnosis, specialized training, and hospital infrastructure. Through partnerships with the City Cancer Challenge and Japan Heart, we leverage the accumulated know-how and experience of patient-centered multidisciplinary team care in Japan to contribute to improving the medical infrastructure of cancer care, which is Chugai’s expertise.

News Release: Chugai Announces New Partnership with City Cancer Challenge Foundation to Enhance the Quality of Patient-Centered Cancer Care in Yangon (Jul 20, 2020) [PDF 197KB]

Activity Reports: Online Workshop on Multidisciplinary Team Care for Healthcare Professionals in Cambodia

C/Can Logo
Japan Heart Logo

Workshop on Multidisciplinary Team Care in Cambodia

Infectious Disease Area

We joined the GHIT Fund, a public-private partnership, to support the research and development of medicines, vaccines, and diagnostics for serious infectious diseases in developing countries by leveraging Japan’s medical technology, innovation, and knowledge. In addition, in order to combat infectious diseases caused by antimicrobial resistance, which is rapidly increasing throughout the world, we joined the AMR Action Fund and provide investment and technical support to small-scale biotechnology companies working on the development of innovative antimicrobial drugs.

News Release: Participation in the Global Health Innovative Technology Fund (GHIT Fund) (Dec 24, 2014) [PDF 120KB]

JPMA News Release: New AMR Action Fund steps in to save collapsing antibiotic pipeline with pharmaceutical industry investment of US$1 billion (Jul 10, 2020)

GHIT Fund Logo

Points Considered for Individual Activities and the Verification/Follow-up Cycle

Chugai values the following points in determining the global health activities it will support and implement.

  • Activities in which Chugai’s strength, technology, or expertise can be utilized
  • Activities that can contribute to the sustainable improvement of healthcare, mainly in low- and middle- income countries

Through these activities, we will implement the verification/follow-up cycle based on local needs as we aim to realize our vision of becoming a Top Innovator in 2030 by both resolving social issues and improving corporate value.

Needs-based Assessment/Follow-up Cycle: Identify needs, design initiatives → Formulate implementation plan and budget, placing top priority on needs → Implement pilot program and assess its effectiveness → Improve program’s autonomy and sustainability → (Return to the beginning)
  • Like
  • Tweet
  • LINE it!
  • E-mail

Global Health

Back to top